LLY Stock Too Cheap At $750?

1. Eli Lilly's growth rate exceeds 30%, significantly outpacing AbbVie's under 5%. This indicates superior performance potential. 2. Lilly's profit margins average 34%, surpassing AbbVie's 26% margins. Higher margins potentially benefit shareholders more. 3. Lilly holds a healthier balance sheet with only 4% debt-to-equity. AbbVie's 20% ratio suggests financial vulnerability. 4. Lilly leads in the obesity drug market, projected to reach $150 billion by 2030. Its current product efficacy fortifies market position. 5. Rapid growth potential may decline, posing risks from increased competition. New therapies could jeopardize Lilly's market dominance.